JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Gesloten

SectorGezondheidszorg

3.72 0.81

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.7199999999999998

Max

3.75

Belangrijke statistieken

By Trading Economics

Inkomsten

-15M

-40M

Verkoop

8.2M

50M

Winstmarge

-80.43

Werknemers

435

EBITDA

-19M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.24% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-578M

543M

Vorige openingsprijs

2.91

Vorige sluitingsprijs

3.72

Nieuwssentiment

By Acuity

50%

50%

155 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mei 2026, 23:47 UTC

Winsten

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 mei 2026, 22:35 UTC

Winsten

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 mei 2026, 23:39 UTC

Marktinformatie

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 mei 2026, 23:34 UTC

Marktinformatie

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 mei 2026, 23:32 UTC

Winsten

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 mei 2026, 23:30 UTC

Marktinformatie

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 mei 2026, 23:20 UTC

Marktinformatie

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 mei 2026, 23:16 UTC

Acquisities, Fusies, Overnames

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 mei 2026, 22:57 UTC

Acquisities, Fusies, Overnames

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 mei 2026, 22:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 mei 2026, 22:45 UTC

Marktinformatie

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 mei 2026, 22:20 UTC

Winsten

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 mei 2026, 22:08 UTC

Winsten

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 mei 2026, 22:05 UTC

Winsten

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 mei 2026, 22:04 UTC

Winsten

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 mei 2026, 22:03 UTC

Winsten

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 mei 2026, 22:03 UTC

Winsten

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 mei 2026, 22:02 UTC

Winsten

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 mei 2026, 22:01 UTC

Winsten

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 mei 2026, 15:06 UTC

Winsten

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

7.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD  7.24%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

155 / 347 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat